Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

CNS Safety

CNS adverse events continue to represent one of the primary reasons for attrition of novel CNS active therapeutics. With our extensive experience of CNS in-vivo pharmacology, Sygnature are well placed to explore the safety profiles of potential novel therapeutics through the design of bespoke studies and the use of established models.

We have significant experience in broad neurofunctional assessments in rodents to evaluate overt CNS safety, as well as focused models to explore directed CNS safety hypotheses. These include the use of the rotarod or the assessment of locomotor activity to explore effects on motoric function, the assessment of effects on seizure threshold to explore proconvulsant risk, and the use of pupillometry to investigate effects on autonomic function. In addition, we also have experience of assessing CNS biomarkers of neuronal function, including systemic prolactin and the intracerebral assessment of neurotransmitters through in-vivo microdialysis.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.